 <h1>Romosozumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to romosozumab: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Injectable)</p><p>Warning: Potential Risk of Myocardial Infarction, Stroke and Cardiovascular DeathRomosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death.Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors.If a patient experiences a myocardial infarction or stroke during therapy, romosozumab-aqqg should be discontinued.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, romosozumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking romosozumab:</p><p>
<i>More common</i>
</p><ul>
<li>Fast heartbeat</li>
<li>fever</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>redness of the skin</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>rapid weight gain</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chest pain or discomfort</li>
<li>confusion</li>
<li>difficulty in breathing</li>
<li>difficulty in speaking</li>
<li>double vision</li>
<li>headache</li>
<li>heavy jaw feeling</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>irregular heartbeat</li>
<li>limp</li>
<li>loosening of a tooth</li>
<li>mood or mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>nausea</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
<li>pain, swelling, tenderness, and bruising in your thigh</li>
<li>seizures</li>
<li>slow speech</li>
<li>stomach cramps</li>
<li>sweating</li>
<li>tremor</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of romosozumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty in moving</li>
<li>muscle pain or stiffness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>lack or loss of strength</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to romosozumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included arthralgia and headache.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the compared with alendronate, but not compared with placebo; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) patients receiving this drug and alendronate, respectively.  These events occurred in women with and without a history of MI or stroke.  Cardiovascular death occurred in 17 (0.8%) and 12 (0.6%) of patients receiving this drug and alendronate, respectively.  Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.  </p>
<p></p>
<p>In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.</p><p><b>Common</b> (1% to 10%): Peripheral edema </p>
<p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction, myocardial death</p><h3>Nervous system</h3><p>Nervous system</p>
<p><b>Common</b> (1% to 10%): Headache, paresthesia </p>
<p><b>Uncommon</b> (0.1% to 1%): Stroke</p><p>During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) of patients receiving this drug and alendronate, respectively.  These events occurred in women both with and without a history of MI or stroke.  Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.  </p>
<p></p>
<p>In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions (angioedema, erythema multiforme, dermatitis, rash, urticaria)</p><p>Hypersensitivity reactions were reported in 6.5% of women in clinical trials; reactions included angioedema and erythema multiforme in less than 0.1%, dermatitis (0.6%), rash (1.1%), and urticaria (0.4%).</p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions</p><p>Injection site reactions occurred in 278 (4.9%) of patients and included injection site pain (1.7%) and erythema (1.4%).</p><h3>Musculoskeletal</h3><p>Osteonecrosis of the jaw occurred in 1 patient receiving this drug during clinical trials.  Atypical femoral fracture also occurred in 1 patient.</p><p><b>Very common</b> (10% or more): Arthralgia (up to 13.1%)</p>
<p><b>Common</b> (1% to 10%): Muscle spasms, neck pain</p>
<p><b>Very rare</b> (less than 0.01%): Osteonecrosis of the jaw, atypical femoral fracture</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><h3>Immunologic</h3><p>During clinical trials, 18.1% of the 5914 postmenopausal women receiving this drug developed antibodies; 4.7% had antibodies classified as neutralizing.  Development of antibodies was associated with lower serum drug concentrations, however, was not associated with changes in safety and efficacy.</p><p><b>Very common</b> (10% or more): Anti-drug antibodies (18.1%)</p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hypocalcemia</p><p>In clinical trials, 2 women receiving this drug experienced hypocalcemia.  Decreases in albumin adjusted serum calcium to less than 8.3 mg/dL were reported in 14 (0.2%) women; there were no reports of adjusted serum calcium less than 7.5 mg/dL.  The nadir in albumin-adjusted serum calcium occurred by month 1 in patients with normal renal function.</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Evenity (romosozumab)." Amgen USA, Thousand Oaks, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about romosozumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous bone resorption inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Romosozumab-aqqg Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Evenity</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Osteoporosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to romosozumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included arthralgia and headache.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the compared with alendronate, but not compared with placebo; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) patients receiving this drug and alendronate, respectively.  These events occurred in women with and without a history of MI or stroke.  Cardiovascular death occurred in 17 (0.8%) and 12 (0.6%) of patients receiving this drug and alendronate, respectively.  Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.  </p><p></p><p>In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.</p><p><b>Common</b> (1% to 10%): Peripheral edema </p><p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction, myocardial death</p><h3>Nervous system</h3><p>Nervous system</p><p><b>Common</b> (1% to 10%): Headache, paresthesia </p><p><b>Uncommon</b> (0.1% to 1%): Stroke</p><p>During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) of patients receiving this drug and alendronate, respectively.  These events occurred in women both with and without a history of MI or stroke.  Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.  </p><p></p><p>In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions (angioedema, erythema multiforme, dermatitis, rash, urticaria)</p><p>Hypersensitivity reactions were reported in 6.5% of women in clinical trials; reactions included angioedema and erythema multiforme in less than 0.1%, dermatitis (0.6%), rash (1.1%), and urticaria (0.4%).</p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions</p><p>Injection site reactions occurred in 278 (4.9%) of patients and included injection site pain (1.7%) and erythema (1.4%).</p><h3>Musculoskeletal</h3><p>Osteonecrosis of the jaw occurred in 1 patient receiving this drug during clinical trials.  Atypical femoral fracture also occurred in 1 patient.</p><p><b>Very common</b> (10% or more): Arthralgia (up to 13.1%)</p><p><b>Common</b> (1% to 10%): Muscle spasms, neck pain</p><p><b>Very rare</b> (less than 0.01%): Osteonecrosis of the jaw, atypical femoral fracture</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><h3>Immunologic</h3><p>During clinical trials, 18.1% of the 5914 postmenopausal women receiving this drug developed antibodies; 4.7% had antibodies classified as neutralizing.  Development of antibodies was associated with lower serum drug concentrations, however, was not associated with changes in safety and efficacy.</p><p><b>Very common</b> (10% or more): Anti-drug antibodies (18.1%)</p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hypocalcemia</p><p>In clinical trials, 2 women receiving this drug experienced hypocalcemia.  Decreases in albumin adjusted serum calcium to less than 8.3 mg/dL were reported in 14 (0.2%) women; there were no reports of adjusted serum calcium less than 7.5 mg/dL.  The nadir in albumin-adjusted serum calcium occurred by month 1 in patients with normal renal function.</p><p id="ref_1">1. "Product Information. Evenity (romosozumab)." Amgen USA, Thousand Oaks, CA. </p><h2>More about romosozumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous bone resorption inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Romosozumab-aqqg Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Osteoporosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>